A

Androlabs

Global men's health-focused pharmaceutical company

CMC Associate Director

Full-Time
£85k - £108k/yr
Expert
London, UK
HybridOffice-based in Central London; remote working is offered from anywhere during August.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • The candidate must have 10–14 years of experience in pharmaceutical manufacturing, technology transfer, and/or product development, with personal end-to-end ownership of multiple CMC programmes.
  • The candidate must have direct CDMO management experience, including commercial negotiation, technical oversight, and performance management.
  • The candidate must have a strong scientific foundation and be able to read, interpret, and challenge batch records, validation reports, stability data, and analytical methods.
  • The candidate must have solid Good Manufacturing Practice knowledge and experience understanding how manufacturing changes interact with regulatory variation requirements.
  • The candidate must have experience contributing to CMC sections of regulatory dossiers and understanding variations and the support required for them.
  • The candidate must have budget management experience, including ownership and management of project-level spend against actuals.
Responsibilities
  • Lead product development and redevelopment from brief to Good Manufacturing Practice readiness, including formulation, process development, and analytical method development.
  • Own technology transfers end to end, from procurement and CDMO selection through process validation and regulatory approval.
  • Define and execute comparability strategies that satisfy internal quality requirements and regulatory variation standards.
  • Drive manufacturing process improvement to enhance efficiency, cost, quality, and supply reliability.
  • Develop CMC strategies with regulatory, clinical, and commercial teams and provide CMC technical input into regulatory submissions.
  • Own the CMC project portfolio, maintaining visibility of status, risks, dependencies, timelines, and budgets across active programmes.
  • Manage the CMC budget by forecasting project costs, approving spend, and reporting to leadership.
  • Source, qualify, and onboard CDMOs and technical partners; negotiate commercial terms and execute agreements.
  • Own the CDMO risk register and ongoing performance management.
  • Build and maintain a network of specialist CMC contractors and consultants for project-specific expertise.
Desired Qualifications
  • Experience with semi-solid or transdermal formulations, including gels, creams, or ointments.
  • Experience with manufacturing new chemical entities.
  • Familiarity with the marketing authorisation holder model and its regulatory obligations.
  • Experience in a small or mid-size specialty pharmaceutical environment with high autonomy.
  • A track record of dual-sourcing or competitive CDMO selection and technology transfer programmes.
  • Experience conducting or overseeing comparability and process validation studies firsthand.

About the company

Androlabs is a global pharmaceutical company focused on men’s health. It develops and sells testosterone replacement and erectile dysfunction medications, aiming to reduce the life expectancy gap between men and women. Beyond products, Androlabs builds an inclusive community for men, addressing knowledge gaps and overlooked health issues, and encourages openness about vulnerability. The company operates in over 20 countries in Europe and Australia and works with healthcare professionals to improve men’s health outcomes. It belongs to the same corporate group as Simple Pharma and seeks new partners who share a passion for men’s health. Its goal is to extend healthy, active lives for men by providing targeted therapies and support, while challenging stereotypes and facilitating better care for men across multiple markets.

Company Size

11-50

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2022

Get referred to Androlabs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 27, 2026, France partnership with Majorelle completed Testavan’s major European rollout.
  • August 13, 2026, EffRx partnership strengthened Swiss distribution and prescriber access.
  • August 25, 2026, UK MHRA authorisation expanded the portfolio and gave sales teams fresh inventory.

What critics are saying

  • Androlabs depends heavily on Testavan; one product breakdown hits the whole business immediately.
  • The 4.6 mg UK authorisation is not a launch, delaying revenue recognition and sales momentum.
  • Testosterone therapies face regulator scrutiny and prescriber caution, risking slow uptake through 2027.

What makes Androlabs unique

  • Androlabs is Tithonia Group's men’s-health specialist, centered on testosterone therapy.
  • It now commercializes Testavan across major European markets, including France, Switzerland, and the UK.
  • The company pairs distribution partnerships with local commercial holders like Majorelle and EffRx.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Paid Vacation

Remote Work Options

Flexible Work Hours

Commuter Benefits

Gym Membership

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

22%

1 year growth

22%

2 year growth

15%
The Pharma Letter
Jul 27th, 2026
Androlabs expands French footprint with Testavan partnership.

Androlabs expands French footprint with Testavan partnership. 27 July 2026 Men's health specialist Androlabs has expanded its European commercial presence through a partnership with Laboratoires Majorelle to market Testavan (testosterone) in France. The agreement makes the testosterone replacement therapy commercially available across Androlabs' main European markets, the company said, completing a regional rollout aimed at improving access to treatments for men's health conditions. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 24 April 2026 23 July 2026 22 July 2026 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 27 July 2026 Company spotlight. A Basel-headquartered global oncology company whose BTK inhibitor zanubrutinib has become the US market-share leader in its class, backed by 78-month CLL follow-up data and approvals across 80 markets. More features in pharmaceutical. 27 July 2026 25 July 2026